Posted 9/16/2019 7:31 AM (GMT -6)
That's great news Fairwind. You really deserved a break. It's wonderful that this promising theranostic has been extended to other cancers since I first heard about the COMPETE trial about a year ago during my introduction to the world of neuroendocrine cancer.
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), also known as carcinoids and islet-cell tumors, are tumors of the neuroendocrine cells that occur in the gastrointestinal (GI) tract. Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide (PRRT) radiopeptides was approved for the treatment of somatostatin-receptor-positive GEP-NETs, including foregut, midgut, and hindgut tumors in adults. PRRT has been used extensively in Europe over the last few decades.
We all need to exercise our vocabulary beyond existing boundaries now and then... you know, to help combat the effects of Lupron brain.
2014-15: PSA's 9, 12, 20, 25, Neg DRE's, false neg TRUS biopsy
6/16: New Uro, MRI Fusion biopsy, 6 pos Rt Base (15-40-100%) G8(4+4)
8/16: DaVinci RP, multifocal EPE, PNI, 11 LN-, 53g/25%, BL SVI, Grp4, pT3b
1/17: Started Lupron ADT, PSA's ~.03
5/17: AMS800 implant, revised 6/17
8/17: 39 tx RapidArc IMRT (70 Gy)
4/18: Dx Radiation Colitis & more
1/18 - 7/19: PSA's <0.008, T~12